LLY

1,031.24

-1.05%↓

JNJ

205.45

+0.09%↑

ABBV

230.21

+2.52%↑

UNH

340.43

+4.83%↑

AZN

90.83

+0.56%↑

LLY

1,031.24

-1.05%↓

JNJ

205.45

+0.09%↑

ABBV

230.21

+2.52%↑

UNH

340.43

+4.83%↑

AZN

90.83

+0.56%↑

LLY

1,031.24

-1.05%↓

JNJ

205.45

+0.09%↑

ABBV

230.21

+2.52%↑

UNH

340.43

+4.83%↑

AZN

90.83

+0.56%↑

LLY

1,031.24

-1.05%↓

JNJ

205.45

+0.09%↑

ABBV

230.21

+2.52%↑

UNH

340.43

+4.83%↑

AZN

90.83

+0.56%↑

LLY

1,031.24

-1.05%↓

JNJ

205.45

+0.09%↑

ABBV

230.21

+2.52%↑

UNH

340.43

+4.83%↑

AZN

90.83

+0.56%↑

Search

AcelRx Pharmaceuticals Inc

Abierto

0

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+532.91% upside

AcelRx Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 dic 2025, 17:29 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dic 2025, 16:21 UTC

Ganancias

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dic 2025, 16:18 UTC

Ganancias

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dic 2025, 23:53 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dic 2025, 22:48 UTC

Ganancias

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dic 2025, 22:12 UTC

Charlas de Mercado

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dic 2025, 22:03 UTC

Charlas de Mercado

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dic 2025, 21:56 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 21:44 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:38 UTC

Charlas de Mercado

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dic 2025, 21:19 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 20:06 UTC

Charlas de Mercado

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dic 2025, 19:55 UTC

Charlas de Mercado

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dic 2025, 19:24 UTC

Charlas de Mercado

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dic 2025, 19:06 UTC

Charlas de Mercado

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dic 2025, 18:27 UTC

Adquisiciones, fusiones, absorciones

Kraken to Acquire Backed Finance AG

2 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 17:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 15:17 UTC

Charlas de Mercado

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dic 2025, 14:47 UTC

Charlas de Mercado

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dic 2025, 14:38 UTC

Charlas de Mercado

Silver Steps Back From Record Levels -- Market Talk

2 dic 2025, 14:31 UTC

Charlas de Mercado
Ganancias

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Comparación entre iguales

Cambio de precio

AcelRx Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

532.91% repunte

Estimación a 12 meses

Media 5 USD  532.91%

Máximo 5 USD

Mínimo 5 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AcelRx Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Finanzas

$

help-icon Live chat